Intravenous Infusions is trading 3.64% up at GHS 0.57, most likely reflecting active healthcare-sector rotation toward defensive assets as broader markets remain under pressure.
- The stock reversed recent weakness after closing at GHS 0.55 on September 10, 2026.
- No new company-specific announcement, earnings release, or transaction was identified for September 15, 2026.
- Recent reporting linked prior volatility to wider healthcare-market trading rather than a distinct corporate catalyst.